Some stocks are up on news of big biotech mergers, but others are down on hearing of the latest difficulties of gene therapy. One thing’s for sure—blood diseases are where it’s at. Speaking of the latest difficulties, we start our January review by going back to that paper out of Stanford about a new obstacle to using CRISPR as a new drug platform. It’s called the human immune system. Major roadblock or small warning light?
January 2018 Review Show with Nathan and Laura: CRISPR vs The Immune System, Biotech Math, and MinION's Big Test
www.mendelspod.com
Mendelspod Podcast
Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who's who in genomics and genomic medicine.
Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who's who in genomics and genomic medicine.Listen on
Substack App
RSS Feed
Appears in episode
Theral Timpson
Recent Episodes
January 2018 Review Show with Nathan and Laura: CRISPR vs The Immune System, Biotech Math, and MinION's Big Test